Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Dynavax Technologies Corporation    DVAX

DYNAVAX TECHNOLOGIES CORPORATION

(DVAX)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Dynavax Technologies Corporation (NASDAQ:DVAX) Files An 8-K Results of Operations and Financial Condition

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 05:26pm EDT

Dynavax Technologies Corporation (NASDAQ:DVAX) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition

Dynavax Technologies Corporation (”Dynavax”) announced in its presentation at the J.P. Morgan 37th Annual Healthcare Conference in San Francisco, California that it expects sales of HEPLISAV-B® (Hepatitis B Vaccine (Recombinant), Adjuvanted) for the fiscal quarter ended December 31, 2018 to be no less than $3.7 million. This amount is preliminary, unaudited, subject to change upon completion of our audit, and may differ from what will be reflected in our audited consolidated financial statements as of and for the quarter and year ended December 31, 2018. Additional information and disclosures would be required for a more complete understanding of our financial position and results of operations as of December 31, 2018.

The information with respect to item 2.02 in this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by us, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.

About Dynavax Technologies Corporation (NASDAQ:DVAX)

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

The post Dynavax Technologies Corporation (NASDAQ:DVAX) Files An 8-K Results of Operations and Financial Condition appeared first on Market Exclusive.

© Market Exclusive 2019, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DYNAVAX TECHNOLOGIES CORPO
03/20Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2..
GL
03/18DYNAVAX TECHNOLOGIES CORP : Creation of a Direct Financial Obligation or an Obli..
AQ
03/18Dynavax Exercises Option for $75 Million in Non-Dilutive Debt
GL
03/06Dynavax to Present at 39th Annual Cowen Healthcare Conference
GL
03/01DYNAVAX TECHNOLOGIES CORP : Material Modification to Rights of Security Holders,..
AQ
02/27DYNAVAX TECHNOLOGIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
02/27DYNAVAX TECHNOLOGIES CORP : Results of Operations and Financial Condition, Finan..
AQ
02/26Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results
GL
02/12DYNAVAX TECHNOLOGIES : to Report Fourth Quarter and Full Year 2018 Financial Res..
PU
02/12DYNAVAX TECHNOLOGIES : to Report Fourth Quarter and Full Year 2018 Financial Res..
AQ
More news
Financials ($)
Sales 2019 51,7 M
EBIT 2019 -132 M
Net income 2019 -132 M
Finance 2019 70,0 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 7,44x
EV / Sales 2020 2,23x
Capitalization 454 M
Chart DYNAVAX TECHNOLOGIES CORPORATION
Duration : Period :
Dynavax Technologies Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DYNAVAX TECHNOLOGIES CORPO
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 30,8 $
Spread / Average Target 333%
EPS Revisions
Managers
NameTitle
Eddie J. Gray Chief Executive Officer & Director
Arnold Lewis Oronsky Chairman
David F. Novack Senior Vice President-Operations & Quality
Michael S. Ostrach Chief Financial & Business Officer, Senior VP
Robert L. Coffman Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
DYNAVAX TECHNOLOGIES CORPORATION-22.30%454
GILEAD SCIENCES1.95%81 339
VERTEX PHARMACEUTICALS9.55%46 409
REGENERON PHARMACEUTICALS4.90%42 066
GENMAB8.01%10 747
SAREPTA THERAPEUTICS INC12.03%9 008